Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 548-557

  Goh, W C ^a   Markee, J ^a   Akridge, R E ^a,b   Meldorf, M ^a,c   Musey, L ^a   Karchmer, T ^a   Krone, M ^a,d   Collier, A ^a   Corey, L ^a   Emerman, M ^a   McElrath, M J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Optiva Corporation   (United States)

^c GREATER BALTIMORE MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INDINAVIR; INTERFERON; LAMIVUDINE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPOSURE; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; FEMALE; HETEROSEXUALITY; HIV ANTIGENS; HIV SERONEGATIVITY; HIV-1; HOMOSEXUALITY, MALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, CCR5; RISK-TAKING; RNA, VIRAL; SEQUENCE DELETION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 17144454549     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314632     Document Type: Article

References (32)

1. 1. Clerici M, Levin JM, Kessler HA, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type I in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992;165:1012-9.
2. 2. Langlade-Demoyen P, Ngo GHN, Ferchal F, Oksenhendler E. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in non-infected heterosexual contact of HIV-infected patients. J Clin Invest 1994;93:1293-7.
3. 3. Mazzoli S, Trabattoni D, Caputo SL, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997;3:1250-7.
4. 4. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
5. 5. Beretta A, Furci L, Burastero S, et al. HIV-1 -specific immunity in persistently seronegative individuals at high risk for HIV infection. Immunol Lett 1996;51:39-43.
6. 6. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996;2:412-7.
7. 7. Fowke KR, Nagelkerke NJ, Kimani J. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996;348: 1347-51.
8. 8. Clerici M, Levin JM, Kessler HA, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994;271:42-6.
9. 9. Pinto LA, Sullivan J, Berzofsky JA, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995;96:867-76.
10. 10. Liu K, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
11. 11. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
12. 12. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
13. 13. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-43.
14. 14. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997;3:23-36.
15. 15. Biti R, French R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-3.
16. 16. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5. Lancet 1997;349:1219.
17. 17. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Lancet 1997;349:1219-20.
18. 18. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiological features of primary HIV infection. Ann Intern Med 1996;125: 257-64.
19. 19. Khadir A, Coutlee F, Saint-Antoine P, Olivier C, Voyer H, Kessous-Elbaz A. Clinical evaluation of amplicor HIV-1 test for the detection of human immunodeficiency virus type I proviral DNA in peripheral blood mononuclear cells. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9: 257-63.
20. 20. Paxton WB, Coombs RW, McElrath MJ, et al. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with ≥400 CD4 lymphocytes: implications for applying measurements to individual patients. J Infect Dis 1997;175:247-54.
21. 21. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim van Dillen PME, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
22. 22. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic T cell responses, viral load, and disease progression in early HIV-1 infection. N Engl J Med 1997;337:1267-74.
23. 23. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997;185:293-303.
24. 24. Kimpton J, Emerman M. Detection of replication-competent and pseudo-typed human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992;66: 2232-9.
25. 25. Wahl SM, Allen JB, Gartner S, et al. Human immunodeficiency virus-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol 1989; 142:3553-9.
26. 26. Vodicka MA, Goh WC, Wu LI, et al. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997;233:193-8.
27. 27. Harrington RD, Geballe AP. Co-factor requirement for human immunodeficiency virus type I entry into a CD4-expressing human cell line. J Virol 1993;67:5939-47.
28. + T cells. Immunol Today 1996;17:217-24.
29. + human cytolytic T tells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990;248:1234-7.
30. 30. McMichael AJ, O'Callaghan CA. A new look at T cells. J Exp Med 1998; 187:1367-71.
31. 31. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
32. 32. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of HIV-1 infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcription inhibitors. J Virol 1997;71:6271-5.